Quarterly ResultJun 15, 2026, 04:36 PM
Conexeu Sciences Reports Increased Net Loss in Q1 2026
AI Summary
Conexeu Sciences Inc. (CNXU) filed its 10-Q report for the period ending April 30, 2026. The company reported a significant increase in net loss for both the three-month and six-month periods compared to the previous year, driven by a substantial rise in operating expenses. Despite the increased losses, cash and cash equivalents saw an increase, though the company's accumulated deficit and limited operating history raise concerns about its going concern status. The company continues to focus on developing cellular therapies for skin restoration.
Key Highlights
- Conexeu Sciences Inc. reported a net loss of $2,304,283 for the three months ended April 30, 2026, compared to $458,050 in the prior year.
- For the six months ended April 30, 2026, the net loss was $4,023,106, up from $748,114 in the same period last year.
- Total operating expenses for the three months ended April 30, 2026, increased to $2,380,368 from $456,981 in the prior year.
- Total operating expenses for the six months ended April 30, 2026, rose to $4,103,327 from $790,434 in the prior year.
- Cash and cash equivalents increased to $6,848,064 as of April 30, 2026, from $4,808,965 as of October 31, 2025.
- The company has an accumulated deficit of $8,544,626 as of April 30, 2026.
- Conexeu Sciences Inc. has a limited operating history and anticipates continued losses, raising substantial doubt about its ability to continue as a going concern.
Price Impact
More from CNXU